Paola Queirolo
Paola Queirolo
Istituto Europeo di Oncologia, IRCCS Milano
Email verificata su ieo.it
Titolo
Citata da
Citata da
Anno
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
8222017
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
PA Ascierto, D Schadendorf, C Berking, SS Agarwala, CML van Herpen, ...
The lancet oncology 14 (3), 249-256, 2013
5642013
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
SJ O'day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, ...
Annals of Oncology 21 (8), 1712-1717, 2010
5052010
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
F Belli, A Testori, L Rivoltini, M Maio, G Andreola, MR Sertoli, G Gallino, ...
Journal of Clinical Oncology 20 (20), 4169-4180, 2002
4752002
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity
G Pietra, C Manzini, S Rivara, M Vitale, C Cantoni, A Petretto, M Balsamo, ...
Cancer research 72 (6), 1407-1415, 2012
2342012
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ...
The Lancet Oncology 15 (4), 436-444, 2014
2282014
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
AM Di Giacomo, PA Ascierto, L Pilla, M Santinami, PF Ferrucci, ...
The lancet oncology 13 (9), 879-886, 2012
2192012
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
J Shi, XR Yang, B Ballew, M Rotunno, D Calista, MC Fargnoli, P Ghiorzo, ...
Nature genetics 46 (5), 482, 2014
2092014
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
M Balsamo, F Scordamaglia, G Pietra, C Manzini, C Cantoni, M Boitano, ...
Proceedings of the National Academy of Sciences 106 (49), 20847-20852, 2009
1992009
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo, M Del Vecchio, M Maio, ...
Annals of Oncology 27 (4), 732-738, 2016
1822016
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
E Simeone, G Gentilcore, D Giannarelli, AM Grimaldi, C Caracò, ...
Cancer immunology, immunotherapy 63 (7), 675-683, 2014
1752014
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
R Dummer, D Schadendorf, PA Ascierto, A Arance, C Dutriaux, ...
The Lancet Oncology 18 (4), 435-445, 2017
1672017
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
E Bajetta, A Di Leo, MG Zampino, MR Sertoli, G Comella, M Barduagni, ...
Journal of clinical oncology 12 (4), 806-811, 1994
1571994
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells
G Pietra, C Manzini, M Vitale, M Balsamo, E Ognio, M Boitano, P Queirolo, ...
International immunology 21 (7), 793-801, 2009
1352009
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
PA Ascierto, E Simeone, VC Sileni, J Pigozzo, M Maio, M Altomonte, ...
Journal of translational medicine 12 (1), 116, 2014
1322014
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
E Bajetta, M Del Vecchio, P Nova, A Fusi, A Daponte, MR Sertoli, ...
Annals of oncology 17 (4), 571-577, 2006
1312006
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
R Danielli, R Ridolfi, V Chiarion-Sileni, P Queirolo, A Testori, R Plummer, ...
Cancer Immunology, Immunotherapy 61 (1), 41-48, 2012
1202012
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
F Spagnolo, P Ghiorzo, L Orgiano, L Pastorino, V Picasso, E Tornari, ...
OncoTargets and therapy 8, 157, 2015
1152015
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
F Spagnolo, P Ghiorzo, P Queirolo
Oncotarget 5 (21), 10206, 2014
1152014
Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma
M Del Vecchio, L Di Guardo, PA Ascierto, AM Grimaldi, VC Sileni, ...
European Journal of Cancer 50 (1), 121-127, 2014
1112014
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20